2 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow BCMA bispecific: new trials by email Literature Review of BCMA bispecific trials Research Report on BCMA bispecific
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis BCMA bispecific - Amyloid Light-chain Amyloidosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 64 | 2026-08-01 | 2026-08-05 |
Immunoglobulin Light-chain Amyloidosis (1) · Multiple Myeloma (1) · Neoplasms (1) · Recurrence (1)
Case Comprehensive Cancer Center (1) · Centre Hospitalier Universitaire de Saint Etienne (1)
France (1) · United States (1)
2025 (1)